2009 Journal Article Catastrophic tumour lysis syndrome following single dose of imatinibKeane, Colm, Henden, Andrea and Bird, Robert (2009). Catastrophic tumour lysis syndrome following single dose of imatinib. European Journal of Haematology, 82 (3), 244-245. doi: 10.1111/j.1600-0609.2008.01186.x |
2009 Journal Article Aspergillus flavus sinusitis in ALLKeane, Colm, Colreavy, Michael, Lynch, Maureen and O'Gorman, Peter (2009). Aspergillus flavus sinusitis in ALL. American Journal of Hematology, 84 (2), 123-123. doi: 10.1002/ajh.21167 |
2008 Conference Publication Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) populationKeane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014 |
2008 Journal Article Neutrophil phagocytosis of Klebsiella pneumoniaeKeane, Colm, Prout, Barry and Bird, Robert (2008). Neutrophil phagocytosis of Klebsiella pneumoniae. British Journal of Haematology, 142 (5), 682-682. doi: 10.1111/j.1365-2141.2008.07213.x |
2008 Journal Article Multi-organ involvement with crystal-storing histiocytosisKeane, C. and Gill, D. (2008). Multi-organ involvement with crystal-storing histiocytosis. British Journal of Haematology, 141 (6), 750-750. doi: 10.1111/j.1365-2141.2008.07131.x |
2006 Conference Publication Thalidomide and dexamethasone in newly diagnosed multiple myelomaMcHugh, Johnny, O'Ceallaigh, Cathal, Keane, Colm, Otridge, Brian W. and O'Gorman, Peter (2006). Thalidomide and dexamethasone in newly diagnosed multiple myeloma. 48th Annual Meeting of the American Society of Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V108.11.5120.5120 |
2006 Journal Article The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilizationKeane, Colm, Gibbs, Simon, Seymour, John F., Mills, Anthony K ., Grimmett, Karen, Van Kuilenberg, Rosita, Russell, Saal, Gill, Devinder, Prince, H. Miles, Marlton, Paula and Mollee, Peter (2006). The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 24 (3), 159-163. doi: 10.1002/hon.784 |
2005 Conference Publication Thalidomide and dexamethasone in newly diagnosed multiple myelomaMcHugh, Johnny, Keane, Colm, Otridge, Brian W., Thornton, Patrick and O'Gorman, Peter (2005). Thalidomide and dexamethasone in newly diagnosed multiple myeloma. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V106.11.5185.5185 |
2004 Conference Publication Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimenMills, AK, Gibbs, S, Keane, C, Mollee, P, Grimmett, K, Van Kuilenburg, R, Saal, R, Gill, D, Prince, HM, Seymour, JF and Marlton, P (2004). Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimen. 46th Annual Meeting of the American-Society-of-Hematology, San Diego Ca, Dec 04-07, 2004. WASHINGTON: AMER SOC HEMATOLOGY. |